FROGG high-risk prostate cancer workshop: Patterns of practice and literature review: Part I: Intact prostate

Journal of Medical Imaging and Radiation Oncology

Volumn 58, Issue 2, 2014, Pages 257-265

  Lehman, Margot ^a   Hayden, Amy J ^b   Martin, Jarad M ^c   Christie, David ^d   Kneebone, Andrew B ^e   Sidhom, Mark ^f   Skala, Marketa ^g   Tai, Keen Hun ^h  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b Westmead Cancer Care Centre   (Australia)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^d Premion   (Australia)

^e SYDNEY CANCER CENTRE   (Australia)

^f Liverpool and Macarthur Cancer Therapy Centres   (Australia)

^g ROYAL HOBART HOSPITAL   (Australia)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

androgen deprivation therapy; pattern of practice survey; prostate cancer; radiation therapy; whole pelvic radiation therapy

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER THERAPY; CLINICAL PRACTICE; COGNITIVE DEFECT; EMOTIONAL DISORDER; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE DISSECTION; LYMPHADENOPATHY; OSTEOPOROSIS; PELVIS LYMPH NODE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION ONCOLOGIST; REVIEW; SEXUAL DYSFUNCTION; TREATMENT DURATION; WORKSHOP; AUSTRALIA; CHEMORADIOTHERAPY; MALE; NEW ZEALAND; ONCOLOGY; ORGANIZATION; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA;

ANDROGEN ANTAGONISTS; AUSTRALIA; CHEMORADIOTHERAPY; CONGRESSES AS TOPIC; DOSE FRACTIONATION; HEALTH CARE SURVEYS; HUMANS; MALE; MEDICAL ONCOLOGY; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS;

EID: 84897581345     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12142     Document Type: Review

References (50)

1. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
2. Mohler J, Bahson R, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200.
3. European Association of Urology. European Association of Urology guidelines for prostate cancer. 2013 update. 2013. [Cited 23 March 2013.] Available from URL: http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer- LR%20March%2013th%202012.pdf
4. Walz J, Joniau S, Chun F, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2010; 107: 765-770.
5. Gnanapragasam V, Mason M, Shaw G, Neal D,. The role of surgery in high-risk localised prostate cancer. BJU Int 2011; 109: 648-658.
6. Thompson I, Tangen C, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomised clinical trial. J Urol 2009; 181: 956-962.
7. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-2027.
8. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930.
9. Van Poppel H, Joniau S,. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008; 53: 253-259.
10. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 (Suppl 1): 22-29.
11. Briganti A, Blute M, Eastham J, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55: 1251-1265.
12. Viani G, Stefano E, Afonso S,. Higher than conventional radiation doses in localised prostate cancer treatment: a meta-analysis of randomised, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-1418.
13. Levegrun S, Jackson A, Zelefsky M, et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2002; 63: 11-26.
14. Zelefsky M, Reuter V, Fuks Z, Scardino P, Shippy A,. Influence of local tumour control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008; 179: 1368-1373.
15. Sathya J, Davis I, Julian J, et al. Randomised trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23: 1192-1199.
16. Hoskin P, Rojas A, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L,. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.
17. Khor R, Duchesne G, Tai KH, et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 2013; 85: 679-685.
18. 192Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: 38-47.
19. Zwahlen DR, Andrianopoulos N, Matheson B, Duchesne GM, Millar JL,. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy 2010; 9: 27-35.
20. Savdie R, Symons J, Spernat D, et al. High dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse. BJU Int 2012; 110 (Suppl 4): 71-76.
21. Hayden A, Martin J, Kneebone A, et al. Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate cancer. J Med Imaging Radiat Oncol 2010; 54: 513-525.
22. Michalski J, Gay H, Jackson A, Tucker SL, Deasy JO,. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010; 76 (Suppl): S123-129.
23. Viswanathan A, Yorke E, Marks LB, Eifel PJ, Shipley WU,. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010; 76 (Suppl): S116-122.
24. Martin J, Frantis J, Eade T, Chung P,. Clinician's guide to prostate IMRT plan assessment and optimisation. J Med Imaging Radiat Oncol 2010; 54: 569-575.
25. Lawton C, DeSilvio M, Roach M 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-655.
26. Pommier P, Chabaud S, Lagrange J, et al. Is there a role for pelvic irradiation in localised prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25: 5366-5373.
27. Morikawa L, Roach M 3rd,. Pelvic nodal radiotherapy in patients with unfavourable intermediate and high-risk prostate cancer: evidence, rationale and future direction. Int J Radiat Oncol Biol Phys 2011; 80: 6-16.
28. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-1073.
29. Horwitz E, Bae K, Hanks G, et al. Ten year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-2504.
30. Radiation Therapy Oncology Group. RTOG 0924 protocol information. Androgen deprivation therapy and high dose radiotherapy with or without whole pelvic radiotherapy in unfavourable intermediate or favourable high risk prostate cancer: A Phase III randomised trial. 2011. [Cited 12 May 2013.] Available from URL: http://www.rtog.org/ClinicalTrials/ProtocolTable/ StudyDetails.aspx?study=0924
31. Mattei A, Fuechsel F, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53: 118-125.
32. Lawton C, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 383-387.
33. Lawton C, Michalski J, El-Naqa I, et al. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 377-382.
34. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD,. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006; (4): CD006019. doi: 10.1002/14651858.CD006019.pub2.
35. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised phase 3 trial. Lancet 2011; 378: 2104-2111.
36. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised Phase III trial. Lancet 2009; 373: 301-308.
37. Bolla A, de Reijke T, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prosate cancer. N Engl J Med 2009; 360: 2516-2527.
38. Williams S, Buyyounouski M, Kestin L, Duchesne G, Pickles T,. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role or tumour stage and radiation dose. Int J Radiat Oncol Biol Phys 2011; 79: 724-731.
39. Keating N, O'Malley A, Smith M,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
40. Tsai H, D'Amico A, Sadetsky N, Chen MH, Carroll PR,. Androgen deprivation therapy for localised prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-1524.
41. D'Amico A, Chen M, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer; a randomised trial. JAMA 2008; 299: 289-295.
42. Nguyen P, Je Y, Schultz F, et al. Association of androgen deprivation therapy with cardiovascular death in Patients with prostate cancer. A meta-analysis of randomised trials. JAMA 2011; 306: 2359-2366.
43. Alibhai S, Yun L, Cheun AM, Paszat L,. Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 2012; 307: 255-256.
44. Dearnaley D, Sydes M, Graham J, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2011; 8: 475-487.
45. Zelefsky M, Pei X, Chou J, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumour control and distant metastases-free survival outcomes. Eur Urol 2011; 60: 1133-1139.
46. Zapatero A, Valcarcel F, Calvo F, et al. Risk adapted androgen deprivation and escalated three-dimension conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICO study. J Clin Oncol 2005; 23: 6561-6568.
47. Pahlajani N, Ruth K, Buyyounouski MK, et al. Radiotherapy doses of 80 Gy and higher are associates with lower mortality in men with Gleason score 8-10 prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1949-1956.
48. Stoyanova R, Pahlajani N, Egleston B, et al. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using two linked nomograms. Cancer 2013; 119: 1080-1088.
49. Nabid A, Carrier N, Martin A, et al. High risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen deprivation: results of a phase III randomised study. J Clin Oncol 2013; 31-6 (February 20 Suppl): 3.
50. Denham J,. RADAR Trial-Randomised Androgen Deprivation and Radiotherapy. Last updated October 2013. [Cited 12 May 2013.] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00193856